Transition from Clinical Trials into RWE in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylarthritis
Communicate Baricitinib and Ixekizumab value proposition in a speaker program setting in order to communicate what the product may mean to people living with Rheumatoid Arthritis Psoriatic Arthritis and Ankylosing Spondylarthritis diseases
FREE
Free